Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.

Company Overview and News

Ferrero may bring brands it acquired from Nestle’s US unit to India

2018-05-29 livemint
New Delhi: Ferrero India Pvt. Ltd, the local unit of Italy-headquartered Ferrero Group, may expand its product offerings for the Indian market with the launch of 20 new confectionery brands, which it had acquired from the US unit of Swiss packaged goods company Nestle SA in January.

Ferrero aims Rs 2,000 crore investment in India, to double distribution network in 2-3 years

2018-05-27 moneycontrol
Italian confectionery major Ferrero will invest another Rs 500 crore to take its total investment to Rs 2,000 crore in India, as part of plans to expand its production facility and distribution network, said a top company official.

Royalty made of nuts | LivingIt

2018-04-20 livingit.euronews
Ohio based artist Steve Casino has given a series of nuts a royal makeover creating tiny replicas of Britain's Royal family. He spent over 362 hours carving and painting the tiny royals.

From merchandise to online club, Delhi Daredevils is going all out for its branding

2018-04-06 moneycontrol
It is not just Ricky Ponting’s effervescence or Gautam Gambhir’s comeback to the team that is keeping Delhi Daredevil's fans engaged. The team management is also rolling out a power-packed branding campaign to maintain the fan interest through the campaign.
KO 1470

What's on TV: Monday, April 2

British TV doctors Chris and Xand van Tulleken provide plenty of high-energy ham in this series, which aims to teach kids about anatomy and medicine. Much of the action involves real British kids and their interactions with real British paramedics and hospital emergency departments; tonight's instalment begins perfectly enough with the case of a four-year-old girl who has managed to get a Tic Tac stuck up her nose.

Related Articles

REPH: Recro Pharma Analysis and Research Report

1h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

1h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="